Generics continue to be under pricing pressure and see higher competitive intensity
Average price erosion were 2-4% QoQ and 8-12% YoY
Specialty portfolio sales of DRL and SUNP continues to be at nascent stage
Consensus guidance is price erosion continues to be regular phenomenon
Benefits from key launches: gRenvela tabs/PFOS (Aurobindo), gStrattera (Aurobindo, Glenmark), gProtonix-IV (Inj-Aurobindo), gLipodox (DRL), gLialda (Cadila), gNitrostat (Glenmark)
Link to the PDF
About Prabhudas Lilladher
Prabhudas Lilladher has a nationwide distribution network, consisting of branches, franchisees and associates, providing a comprehensive gamut of financial services in the Institutional and Retail domain. Their services includes Equity, derivatives; margin funding, mutual funds, PMS, IPOs and online trading.
For more information please write in to email@example.com
Disclaimer: The author has taken due care and caution to compile and analyse the data. The opinions expressed above are only the views of the author, and not a recommendation to buy or sell. Neither the author nor IndiaNotes.com accept any liability whatsoever arising from the use of any of the above contents.